XtenCHO ™ Race Starter kit

Description of XtenCHO ™ Race Starter kit

The XtenCHO™ Race mammalian expression system has been carefully engineered to offer a rapid and cost-effective solution for the expression of recombinant proteins. It is particularly advantageous for a wide range of applications, including small- to medium-scale production and the swift screening of drug candidates and protein variants.

Drawing on over 28 years of experience, XtenCHO™ Race combines the high expression potential and robustness of a novel Chinese Hamster Ovary (CHO) cell line with the exceptional efficiency of our proprietary transfection reagent, XtenFect™. This synergy provides several benefits, including:
• Yield enhancements of up to 10 times compared to other commercial systems*
• Improved plasmid retention (exceeding 14 days of transient gene expression – TGE) achieved through highly effective transfection that preserves cell viability, enhances plasmid stability, and boosts protein expression without the need for additional feeds
• Short protocol in 8 days only
• Simplified protocols with fewer steps, designed to streamline and accelerate your workflow, backed by comprehensive and responsive technical support
• Removal of case-by-case optimization due to the high expression levels associated with the pXen1 vector
• Optimal protein folding and human-like post-translational modifications
• Cost-efficient biopharmaceutical-grade production
• Enhanced safety due to the superior viral resistance of CHO cells compared to Human Embryonic Kidney (HEK) cells
• Flexible and scalable production options (ranging from 1 mL to 10 L) customized to meet your specific needs
• Global shipping within 24 hours or less

When compared to other commercial systems, XtenCHO™ has shown exceptional performance, achieving yield increases of 1.5 to 9.7-fold*:
• Record productivity for IgG-like antibodies (1.8 g/L for Garetosmab)
• Bispecific antibodies exceeding 100 mg/L
• Humanized antibody variants surpassing 200 mg/L
• Non-antibody proteins yielding over 100 mg/L for ACE2 with excellent enzymatic activity
• Pentameric IgM antibodies
• And more

The XtenCHO™ Race kit features our proprietary, chemically defined expression media that is free from animal-derived components, ensuring optimal performance. Additionally, it includes our effective expression booster, XtenCHO™ Race Enhancer, along with control plasmids, providing you with comprehensive control and flexibility in your processes.

What are the advantages of using XtenCHO™ Race in your biopharmaceutical research initiatives?

Historically, biomolecules entering phase I clinical trials have encountered a disappointingly low success rate of less than 10%. In contrast, nearly three-quarters of biopharmaceuticals that have received approval are produced using CHO-based systems. Analysis of the data indicates that CHO-based platforms may effectively address common developmental challenges that impede success.
XtenCHO™ Race facilitates the production of high-quality recombinant proteins, enabling thorough early bioanalysis, which aids in the prompt identification of potential developability issues and enhances the likelihood of success.
With exceptionally high yields, rapid production capabilities, and protein folding and quality comparable to clinical-grade biopharmaceuticals, XtenCHO™ is well-suited for the swift evaluation of drug candidates or protein variants derived from random or targeted mutagenesis.

Why opt for XtenCHO™ Race in your research applications?

Although bioassays serve as critical research and monitoring instruments within various industries—including healthcare, food production, and environmental analysis—they frequently depend on antibodies sourced from hybridomas, which can result in decreased purity and limited accuracy and precision. However, advancements are on the horizon. Through its CHO-based recombinant expression, XtenCHO™ enables higher yields, better batch-to-batch consistency, and improved purity in a cost-effective manner. With streamlined protocols, XtenCHO™ Race integrates smoothly into your existing workflows and adjusts to your specific protein production requirements.

XtenCHO™ Race outperforms up to 6X (Cixutumumab and Peresolimab)

Crude production yields in mg/L obtained in 24-well plates cultures without feeding (Octet Analysis) Yields in flask (better aeration) will be 1.5 to 2.5 Higher for Human/humanized IgG1/IgG4 (depending on the antibody considered)